ZyVersa Therapeutics, Inc. reported earnings results for the full year ended December 31, 2023. For the full year, the company reported net loss was USD 98.3 million compared to USD 14.12 million a year ago. Basic loss per share from continuing operations was USD 1,089.7.
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
4.4 USD | +4.76% | -16.82% | -51.11% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-51.11% | 3.34M | |
+8.63% | 114B | |
+13.17% | 107B | |
-12.76% | 22.22B | |
-2.39% | 21.28B | |
-5.10% | 18.8B | |
-7.19% | 17.51B | |
-39.93% | 17.17B | |
+6.67% | 14.14B | |
+33.90% | 12.2B |
- Stock Market
- Equities
- ZVSA Stock
- News ZyVersa Therapeutics, Inc.
- ZyVersa Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023